핵의학

본문글자크기
  • 2017년 12월호
    [Thyroid.] Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.

    부산의대 / 이수인, 김대영, 김재호*, 김성장*

  • 출처
    Thyroid.
  • 등재일
    2017 Nov
  • 저널이슈번호
    27(11):1424-1432. doi: 10.1089/thy.2016.0414. Epub 2017 Oct 19.
  • 내용

    바로가기  >

    Abstract

    BACKGROUND:
    Anaplastic thyroid cancer (ATC) has a very poor prognosis due to its aggressive nature and resistance to conventional treatment. Radiotherapy and chemotherapy are not fully effective because of the undifferentiated phenotype and enhanced drug resistance of ATC. The objective of this study was to evaluate the involvement of Krüppel-like factor 4 (KLF4), a stemness-associated transcription factor, in the undifferentiated phenotype and drug resistance of ATC.

    METHODS:
    ATC cells were compared to papillary thyroid cancer cells in drug resistance and gene expression. The effects of KLF4 knockdown in ATC cells on in vitro and in vivo drug resistance were measured. The effects of KLF4 overexpression and knockdown on ABC transporter activity were determined.

    RESULTS:
    ATC cells, such as HTH83, 8505C, and SW1736, exhibited higher resistance to the anticancer drug paclitaxel and higher expression of KLF4 than TPC-1 papillary thyroid cancer cells. Knockdown of KLF4 expression in ATC cells increased the expression of the thyroid-specific differentiation genes, such as thyrotropin receptor, thyroid peroxidase, thyroglobulin, and sodium-iodide symporter. Knockdown of KLF4 expression in ATC cells decreased the resistance to doxorubicin and paclitaxel, and reduced ABC transporter expression. Luciferase reporter assay results showed that KLF4 overexpression increased ABCG2 promoter activity, which was abolished by KLF4 knockdown. A tumorigenicity assay showed that the combination of paclitaxel treatment and KLF4 knockdown significantly decreased tumor mass originated from HTH83 cells in mice.

    CONCLUSIONS:
    ATC cells show high expression of KLF4, and KLF4 expression is necessary for maintaining the undifferentiated phenotype and drug resistance in vitro and in vivo. The present study identifies KLF4 as a potential therapeutic target for eliminating ATC cells.

     


    Author information

    Lee SI1, Kim DK1, Seo EJ1, Choi EJ1, Kwon YW1, Jang IH2, Lee JC3, Kim HY4,5, Shong M6, Kim JH1,5, Kim SJ7.
    1 Department of Physiology, School of Medicine, Pusan National University , Yangsan, Republic of Korea.
    2 Department of Oral Biochemistry and Molecular Biology, School of Dentistry, Pusan National University , Yangsan, Republic of Korea.
    3 Department of Otolaryngology, Pusan National University Yangsan Hospital , Yangsan, Republic of Korea.
    4 Department of Surgery, Pusan National University Yangsan Hospital , Yangsan, Republic of Korea.
    5 Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital , Yangsan, Republic of Korea.
    6 Division of Endocrinology, Department of Internal Medicine, Chungnam National University School of Medicine , Daejeon, Republic of Korea.
    7 Department of Nuclear Medicine, Pusan National University Yangsan Hospital , Yangsan, Republic of Korea.

  • 키워드
    KLF4; anaplastic thyroid cancer; cancer stem cell; chemoresistance
  • 편집위원

    갑상선암 중 미분화갑상선암은 예후가 매우 불량한 악성종양으로 분화갑성선암과 달리 방사성요오드치료가 효과적이지 못합니다. 위 연구는 미분화 갑상선암의 유지에 KLF4가 중요한 역할을 수행하며, 이를 억제하면 항암치료능이 높아짐을 보여준 연구입니다.
    갑상선암에 관심을 가진 연구자들에게 큰 관심을 끌 논문으로 생각되며, KLF4의 억제가 갑상선분화와 관련성 또한 추가 연구가 진행될 수 있을 수 있으며, 추가연구가 시행될 수 있을 것입니다.

    덧글달기2017-12-12 15:37:01

  • 덧글달기
    덧글달기
       IP : 13.59.62.219

    등록